Markets:

Overview

News

Currencies

International

Treasuries

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

26.98 -0.66 (-2.41%)

Streaming Delayed Price Updated: 2:57 PM EDT, Jul 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Alto Neuroscience, Inc. Common Stock

< Previous 1 2 Next >

Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing ↗

May 27, 2026

COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office...

Via The Motley Fool

Topics Regulatory Compliance

A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗

January 15, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

December 26, 2025

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

Via Chartmill

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗

November 17, 2025

Via Benzinga

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

November 17, 2025

Via Benzinga

Alto Neuroscience Inc (NYSE:ANRO) Reports Narrower Q3 2025 Loss and Accelerated Pipeline Progress ↗

November 12, 2025

Alto Neuroscience reports a narrower-than-expected Q3 2025 loss and advances its precision psychiatry pipeline, with cash extending into 2028.

Via Chartmill

These stocks are moving in today's session ↗

October 20, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 20, 2025

Via Benzinga

Top movers analysis in the middle of the day on 2025-10-20: top gainers and losers in today's session. ↗

October 20, 2025

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Gapping stocks in Monday's session ↗

October 20, 2025

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 03, 2025

Via Benzinga

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug ↗

October 03, 2025

FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

Via Stocktwits

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 02, 2025

Via Benzinga

This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

September 29, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

Via Benzinga

This VSE Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

September 29, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

Via Benzinga

Alto Neuroscience Posts Q2 Net Loss ↗

August 13, 2025

Via The Motley Fool

Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal ↗

June 03, 2025

Alto Neuroscience acquires Chase's treatment-resistant depression drug portfolio for $1.75 million upfront; early data shows strong efficacy for lead candidate ALTO-207.

Via Benzinga

Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock ↗

March 03, 2025

While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials.

Via Stocktwits

This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

December 16, 2024

Via Benzinga

Nasdaq Down 2%; US Crude Stocks Increase ↗

October 23, 2024

Via Benzinga

Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform ↗

October 23, 2024

Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the company plans further data analysis and studies.

Via Benzinga

Gold Moves Lower; AT&T Earnings Top Views ↗

October 23, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 23, 2024

Via Benzinga

Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss ↗

October 23, 2024

Via Benzinga

Topics Stocks

Enphase Energy Posts Downbeat Results, Joins McDonald's, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 23, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 23, 2024

Via Benzinga

Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket ↗

October 23, 2024

Via Benzinga

ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024 ↗

August 13, 2024

ANRO stock results show that Alto Neuroscience beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On ↗

June 10, 2024

Under-the-radar stocks offer incredible chances at massive returns with these shares representing compelling choices for investors.

Via InvestorPlace

ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024 ↗

May 14, 2024

ANRO stock results show that Alto Neuroscience missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.